Company webinar

Prescient Therapeutics (ASX:PTX)

Watch our webinar with Prescient Therapeutics, featuring Prescient CEO and MD Steven Yatomi-Clarke. Steven will be holding a webinar to outline the company’s diversified portfolio of later stage and emerging assets for cancer treatment. A presentation followed by live Q&A with the audience.

Date
March 29, 2023
Time
Where
Online
Entry
Free
Steven Yatomi-Clarke
Steven Yatomi-Clarke
CEO and MD, Prescient Therapeutics (ASX:PTX)

About the company

Prescient Therapeutics (ASX: PTX) is emerging as a key player of the cell therapy revolution, featuring a broad portfolio of well-advanced assets developed with world-leading partners, including Yale, UPenn, Oxford University and Peter MacCallum.

Prescient’s world-class portfolio boasts a diversified range of assets with two first-in class targeted therapies, PTX-100 and PTX-200, that are currently in clinical development and showing encouraging activity in diseases of unmet need. Prescient owns the exclusive rights to two vital CAR-T platform technologies, OmniCAR and CellPryme - both with the potential to elevate and enhance CAR-T therapies - effectively giving them a ‘shovels to the gold rush’ advantage in a burgeoning area of cancer treatment.

Key topics

Watch the recording

More webinars

All webinars →

Go beyond the presentation

Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.

Explore our services →